Tags

Type your tag names separated by a space and hit enter

Influence of dialysis modalities on serum AGE levels in end-stage renal disease patients.

Abstract

BACKGROUND

The accumulation of advanced glycation end-products (AGEs) in end-stage renal disease (ESRD) influenced by dialysis modalities is of current interest. Highly permeable membranes in haemodialysis or haemofiltration should be able to eliminate circulating AGEs as well as their AGE precursors more efficiently.

METHODS

In our study, 10 non-diabetic and 10 diabetic ESRD patients were on haemodialysis with low-flux membranes (LF) followed by a cross-over haemodialysis with high-flux or super-flux polysulfone membranes (HF, SF) for 6 months each. We measured the protein-bound pentosidine and free pentosidine serum levels by high-performance liquid chromatography (HPLC) as well as the serum AGE peptide, AGE-beta(2)-microglobulin and beta(2)-microglobulin concentrations, using ELISA assays.

RESULTS

All parameters investigated were significantly higher in dialysis patients than in healthy subjects. The reduction rates during a single dialysis session were found to be higher using the SF than those obtained with the HF (free pentosidine 82.4+/-7.3 vs 76.6+/- 8.7%; AGE peptides 79.7+/-7.7 vs 62.3+/-14.7%; AGE-beta(2)-microglobulin 64.0+/-16.5 vs 45.4+/-17.7%; beta(2)-microglobulin 70.5+/-5.6 vs 58.2+/-6.0%). The protein-bound pentosidine levels remained constant over the respective dialysis sessions. In the 6-month treatment period with the SF, decreased pre-dialysis serum levels of protein-bound pentosidine, free pentosidine and AGE peptides were observed in non-diabetics and diabetics as compared with values obtained with the LF. The respective pre-dialysis AGE-beta(2)-microglobulin concentrations decreased insignificantly, whereas those of beta(2)-microglobulin were significantly lower. Using the HF dialyser, only moderate changes of the parameters measured were noted.

CONCLUSION

Treatment with the biocompatible polysulfone SF dialyser seems to be better suited to lower serum AGE levels and to eliminate their precursors.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Internal Medicine IV, Friedrich Schiller University of Jena, Erlanger Allee 101, D-07740 Jena, Germany.

    , , , , ,

    Source

    MeSH

    Adult
    Aged
    Arginine
    Biocompatible Materials
    Cross-Over Studies
    Female
    Glycation End Products, Advanced
    Humans
    Kidney Failure, Chronic
    Lysine
    Male
    Membranes, Artificial
    Middle Aged
    Polymers
    Renal Dialysis
    Serum Albumin
    Sulfones
    beta 2-Microglobulin

    Pub Type(s)

    Journal Article

    Language

    eng

    PubMed ID

    11328907

    Citation

    Stein, G, et al. "Influence of Dialysis Modalities On Serum AGE Levels in End-stage Renal Disease Patients." Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association, vol. 16, no. 5, 2001, pp. 999-1008.
    Stein G, Franke S, Mahiout A, et al. Influence of dialysis modalities on serum AGE levels in end-stage renal disease patients. Nephrol Dial Transplant. 2001;16(5):999-1008.
    Stein, G., Franke, S., Mahiout, A., Schneider, S., Sperschneider, H., Borst, S., & Vienken, J. (2001). Influence of dialysis modalities on serum AGE levels in end-stage renal disease patients. Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association, 16(5), pp. 999-1008.
    Stein G, et al. Influence of Dialysis Modalities On Serum AGE Levels in End-stage Renal Disease Patients. Nephrol Dial Transplant. 2001;16(5):999-1008. PubMed PMID: 11328907.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Influence of dialysis modalities on serum AGE levels in end-stage renal disease patients. AU - Stein,G, AU - Franke,S, AU - Mahiout,A, AU - Schneider,S, AU - Sperschneider,H, AU - Borst,S, AU - Vienken,J, PY - 2001/5/1/pubmed PY - 2001/7/6/medline PY - 2001/5/1/entrez SP - 999 EP - 1008 JF - Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association JO - Nephrol. Dial. Transplant. VL - 16 IS - 5 N2 - BACKGROUND: The accumulation of advanced glycation end-products (AGEs) in end-stage renal disease (ESRD) influenced by dialysis modalities is of current interest. Highly permeable membranes in haemodialysis or haemofiltration should be able to eliminate circulating AGEs as well as their AGE precursors more efficiently. METHODS: In our study, 10 non-diabetic and 10 diabetic ESRD patients were on haemodialysis with low-flux membranes (LF) followed by a cross-over haemodialysis with high-flux or super-flux polysulfone membranes (HF, SF) for 6 months each. We measured the protein-bound pentosidine and free pentosidine serum levels by high-performance liquid chromatography (HPLC) as well as the serum AGE peptide, AGE-beta(2)-microglobulin and beta(2)-microglobulin concentrations, using ELISA assays. RESULTS: All parameters investigated were significantly higher in dialysis patients than in healthy subjects. The reduction rates during a single dialysis session were found to be higher using the SF than those obtained with the HF (free pentosidine 82.4+/-7.3 vs 76.6+/- 8.7%; AGE peptides 79.7+/-7.7 vs 62.3+/-14.7%; AGE-beta(2)-microglobulin 64.0+/-16.5 vs 45.4+/-17.7%; beta(2)-microglobulin 70.5+/-5.6 vs 58.2+/-6.0%). The protein-bound pentosidine levels remained constant over the respective dialysis sessions. In the 6-month treatment period with the SF, decreased pre-dialysis serum levels of protein-bound pentosidine, free pentosidine and AGE peptides were observed in non-diabetics and diabetics as compared with values obtained with the LF. The respective pre-dialysis AGE-beta(2)-microglobulin concentrations decreased insignificantly, whereas those of beta(2)-microglobulin were significantly lower. Using the HF dialyser, only moderate changes of the parameters measured were noted. CONCLUSION: Treatment with the biocompatible polysulfone SF dialyser seems to be better suited to lower serum AGE levels and to eliminate their precursors. SN - 0931-0509 UR - https://www.unboundmedicine.com/medline/citation/11328907/Influence_of_dialysis_modalities_on_serum_AGE_levels_in_end_stage_renal_disease_patients_ L2 - https://academic.oup.com/ndt/article-lookup/doi/10.1093/ndt/16.5.999 DB - PRIME DP - Unbound Medicine ER -